1. Nakatani Y, Maeda M, Matsumura M, Shimizu R, Banba N, Aso Y, et al. Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes Metab. 2...
While previous studies have reviewed notable cutaneous adverse effects with other antidiabetic medications, little is known about GLP-1 agonist-induced cutaneous reactions. Nevertheless, rare but significant cutaneous adverse reactions have been reported, including but not limited to dermal hypersensitivity ...
et al. 2015. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res Clin Pract 110:26- 37.
[22] Wharton, Sean, et al. "Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity." New England Journal of Medicine (2023).[23] Jansen, Kirsten M., et al. "Impact of GLP-1 receptor agonist versus omega-3 fatty acids supplement on obesity-induced alterations of mitocho...
文章导读：司美格鲁肽（Semaglutide, 最初译为索马鲁肽）由糖尿病制药巨头诺和诺德开发，是一种新型的长效胰高糖素样肽‑1受体激动剂（GLP‑1RA , glucagon‑like peptide‑1 receptor agonist），也称胰高糖素样肽‑1类似物（GLP-1类似物）。2017年12月，司美格鲁肽首次在美国FDA获批上市，2018年2月于...
Many people will be prescribed a GLP-1 receptor agonist only after it becomes clear that they need more than just metformin to control their blood sugar. But it’s becoming more common for new diabetes patients to begin using a GLP-1 receptor agonist immediately. ...
M. A., & D'Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist ...
[10] Kalra S, et al. A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus. Diabetes Ther. 2020 Sep;11(9):1965-1982. [11] Chao AM, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023 Apr;33(3)...
GLP-1类多肽减肥药 最新的抗肥胖药物靶向GLP-1受体,胰高血糖素样肽-1 受体(GLP1R)是一种在胰腺 β 细胞和大脑神经元上发现的受体蛋白,它通过增强胰岛素分泌参与控制血糖水平。 胰高血糖素样肽1受体激动剂(GLP-1 receptor agonists, 简称GLP-1肽),通过增强β胰腺细胞分泌胰岛素和抑制α胰腺细胞释放胰高血糖素来...
Unlocking the broad health benefits and risks of GLP-1 receptor agonist drugs Nature Medicine Research Briefing 23 Jan 2025 Sections Figures References Abstract Data availability Code availability Change history References Acknowledgements Author information Ethics declarations Peer review Additional information...